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Introduction
Tibolone is a new treatment with a unique pharmaco-
logic profile licensed for the relief of climacteric symp-
toms and the prevention of osteoporosis in postmeno-
pausal women [1]. Although it is frequently described
as a hormone therapy (HT) product, recent research
provides a clearer insight into the mechanism of action
of tibolone, which is significantly different from those
of conventional HT, such as estrogen with or without
progestin [2]. Therefore, the clinical profile has led to its
classification as a selective tissue estrogenic activity
regulator (STEAR) [1]. Tibolone is a synthetic steroid
with tissue-selective estrogenic, progestogenic, and
androgenic properties. It is metabolized into three main
metabolites: the b-4 isomer, and the 3-_ and 3-` hydroxy
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metabolites. Each metabolite has different binding to
the estrogenic, progestogenic, and androgenic receptors
[3]. The 3-_ and 3-` hydroxy metabolites exert estro-
genic activity, but in a tissue-selective manner [3–12].
The b-4 isomer shows both androgenic and pro-
gestogenic effects [2], which avoids stimulation of the
endometrium [1,11]. Tibolone is easy to use: only a
single tablet containing 2.5 mg tibolone is needed each
day [8].
Climacteric symptoms sometimes bother peri-
menopausal women, resulting in severe interference in
their quality of life, and HT is an effective method of re-
lieving most climacteric symptoms. However, concerns
have arisen regarding the possible association between
breast cancer and HT. The largest meta-analysis to
date, which included more than 90% of the literature
[13], concluded that HT increases the risk of developing
breast carcinoma and that this risk increases with the
increasing duration of HT use. Once HT is stopped, this
risk decreases, and it largely disappears by 5 years after
cessation. Recent findings from the Women’s Health
Initiative study show an increased incidence of invasive
breast cancer during HT [14]. Although menopause is
a natural event in women, some women suffer from
symptoms that significantly affect their lives. Al-
though circulating levels of estrogen are reduced in
postmenopausal women, the breast tissue of post-
menopausal women is able to synthesize estrogens
locally, which explains why the risk of breast cancers is
not minimized after menopause. In fact, estradiol is
the main factor supporting the growth and evolution
of breast cancers. One pathway involved in the
transformation of estradiol is the sulfatase pathway,
which transforms estrone sulfate to estradiol [9],
especially after menopause. Tibolone and its metabolites
are very potent inhibitors of the conversion of estrone
sulfate to estradiol in the hormone-dependent breast
cancer cell [9,10]. Tibolone metabolites regulate the
activity of local enzymes normally involved in the
production of active estrogens in the breast [12].
Tibolone has a different effect from conventional HT in
the breast. It does not seem to stimulate breast tissue
and might have an inhibitory effect on the growth of
human breast tumor cells in vitro, and animal breast
tumors [12], in addition to slowing down the
proliferation rate and increasing differentiation and
apoptosis [9]. In addition to the possibility of no
increased risk of breast cancer, tibolone rarely causes
breast tenderness and does not increase breast density
[3,15]. Tibolone reportedly has a favorable tolerability
profile [16]. Only a minority of women treated with
tibolone experience vaginal bleeding, and the bleeding
is mild and transient [4]. The advantageous tolerability/
safety profile increases the acceptability of tibolone
treatment and improves short- and long-term adher-
ence to treatment [17]. However, these studies do not
provide data about women living in Taiwan. There-
fore, it is reasonable to evaluate the compliance with
and efficacy of tibolone in symptomatic perimenopau-
sal women in Taiwan.
Methods
Before initiation of the study, approval was granted by
the independent ethics committee and institutional
review board of the hospital. Women with a natural or
surgically induced menopause who visited the hospital
between September 2003 and June 2004 due to
climacteric complaints were recruited into the study,
whether they had received other HT or not. Once re-
cruited, the case report form was immediately used to
record baseline data, including basic demographic data,
and the patient was scheduled for follow-up at the end
of the third and sixth months of therapy with 2.5 mg
tibolone daily. The case report form was used to record
whether breast tenderness, insomnia, libido changes,
mood swings, or bleeding episodes occurred during the
study period. Weight was measured at the first visit and
at the end of the sixth month for comparison.
Results
A total of 289 women in natural or surgical perimeno-
pause were recruited into this study. Of these, 275
were still taking tibolone at the end of the study, which
demonstrated a high retention rate (95.2%) (Figure 1).
The rate of breast tenderness was significantly reduced
from 26.5% at baseline to 2.8% at the end of the study.
Figure 1. Symptoms and signs at baseline and at the end of 3
and 6 months of tibolone treatment (n = 275).
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The rate of insomnia decreased from 50.5% at baseline
to 20.4% at the end of the study, and bleeding episodes
decreased from 87.4% at baseline to 39.4% at the end of
the study. The rate of mood instability was significantly
reduced, from 84.1% at baseline to 44.3% at the end
of the study. Libido (sexual satisfaction) significantly
improved from 15.9% at baseline to 61.6% at the end
of the study, which is a unique profile of tibolone due
to the androgenic effect of its b-isomer. Thirty women
(10.4%) had improved vaginal dryness. Ten women
(3.5%) developed an allergic reaction, three of whom
dropped out of the study. One woman (0.3%) had
breast tenderness and three (1%) complained of gastro-
intestinal disturbance. Three women (1%) had an attack
of acne during therapy. Body weight changes in the
women varied; most women (84.1%) had a weight
increase ranging from 0.5 to 3 kg (Figure 2). Fourteen
subjects dropped out for the following reasons: three
for acne and/or an allergic reaction; four for intolerable
weight gain and/or water retention; one due to head-
ache and dizziness; and six for other personal reasons.
During the 6-month evaluation period, seven women
(2.4%) had been prescribed a half dose (1.25 mg) for
personal reasons. No severe adverse events were re-
ported during the observation period.
Discussion
Numerous clinical studies have shown that tibolone has
beneficial effects in relation to climacteric symptoms
and vaginal atrophy in postmenopausal women; relief
from climacteric symptoms develops within 3–5 weeks,
and the maximum effect is usually seen by 3 months
[16]. In addition, tibolone shows beneficial effects on
mood and sexual wellbeing [5–7,17]. The results of this
study demonstrate a similar positive effect in improving
insomnia, libido, and mood instability and, of most
importance, there was a high rate of continuous use
of tibolone. Moreover, a low dose (1.25 mg/day) also
seemed to be effective. In this observational study, seven
women were satisfied with this low-dose treatment,
which is in agreement with a previous report showing
that tibolone induced a decrease in the frequency and
intensity of climacteric symptoms, leading to statistic-
ally significant differences compared to placebo, at
doses of 1.25 mg and higher [18].
Concerning irregular vaginal spotting and/or possi-
ble unwanted pathologic changes to the endometrium,
tibolone therapy is reported to have high rates of
amenorrhea after 10 years, with minimal evidence of
adverse effects on endometrial pathology [19]. In this
study, we found that irregular bleeding episodes were
markedly decreased both during and at the end of
treatment.
In terms of biochemical changes in the blood,
tibolone is reported to lower lipoprotein(a), fibrinogen,
and plasminogen activator inhibitor-1 levels and to
improve glucose tolerance, insulin sensitivity, and
endothelial function. However, it also lowers high-
density lipoprotein cholesterol by more than 20% [20].
Therefore, the long-term impact of tibolone on the risk
of coronary heart disease is not known and needs to be
studied [20]. We did not evaluate changes in blood
biochemistry. However, significantly increased body
weight was noted in this study, in disagreement with a
previous report showing that tibolone is not associated
with weight gain [15]. Due to the short-term follow-up,
Figure 2. Weight change from baseline to the end of 6 months of tibolone treatment (n = 275).
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we do not know the long-term effects of the increased
body weight on these women taking tibolone, but we
are highly concerned about these changes. We believe,
therefore, that changes in body weight should be further
studied and evaluated.
Tibolone, compared with conventional HT such as
estrogen with or without progestogen, seems to be a
relatively safe medication in terms of the risk of breast
cancer. The Million Women Study shows that the
incidence of breast cancer is significantly increased in
current users of preparations containing estrogen only
(adjusted relative risk, 1.30 [95% confidence interval,
1.21–1.40]; p < 0.0001), estrogen/progestogen (2.00
[1.88–2.12]; p < 0.0001), and tibolone (1.45 [1.25–
1.68]; p < 0.0001), but the magnitude of the associated
risk was substantially greater for estrogen/progestogen
than for other types of HT (p < 0.0001) [21–23]. An
increase in mammographic density should be regarded
as an unwanted side effect of HT [15]. In contrast to
estrogen/progestogen treatment, tibolone seems to have
little stimulating effect on breast tissue [15]. A recently
published paper on the long-term effects of tibolone on
mammographic density elaborates tibolone’s unique
effects on the breast, and suggests that tibolone seems
to have a minimal effect on mammographic density [3].
All of the above suggest that tibolone has an advantage
over conventional HT in terms of breast cancer risk.
Tamoxifen is often used as adjuvant therapy and/or
preventive therapy for breast cancer. Unfortunately,
many women with breast cancer suffer vasomotor
symptoms rather than risk recurrence with conventional
HT. In a small randomized controlled trial in women
with early breast cancer undergoing adjuvant tamoxi-
fen treatment, tibolone reduced hot flushes and night
sweats and improved quality of life compared with
placebo [24]. Moreover, tibolone prevents the increase
in hot flushes in postmenopausal women given tamoxi-
fen following surgery for breast cancer without unto-
ward effects on the endometrium [25].
Tibolone prevents bone loss and increases bone
mineral density in early and late postmenopausal women
[4,8,26]. Since we did not evaluate bone mineral density
during or at the end of tibolone treatment, we do not
know the changes in bone mineral density in this short-
term evaluation.
Some limitations of this study should be clarified.
First, this is a relatively small study population, which
may not provide strong evidence showing the true
benefits of tibolone. Secondly, prescription behavior
was not clearly identified within the scope of the
measurement. Thirdly, increased body weight seems to
be the major unwanted effect in this trial, and because
of the small sample and dropouts, this issue should
be re-evaluated in a future study. Fourthly, this is a de-
scriptive study, and we did not use scientific statistics
to analyze the data.
This study shows the efficacy of tibolone in insom-
nia, mood, and libido improvement, as well as its good
tolerability (less breast tenderness and fewer bleeding
episodes) in postmenopausal women.
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